[[File:Cellular iron homeostasis.png|thumb|left|TfR1 = transferrin receptor 1 in [[Human iron metabolism]].]]
[[File:Cellular iron homeostasis.png|thumb|left|TfR1 = transferrin receptor 1 in [[Human iron metabolism]].]]
TfR1 is a transmembrane glycoprotein composed of two disulfide-linked monomers joined by two disulfide bonds. Each monomer binds one holo-[[transferrin]] molecule creating an iron-Tf-TfR complex which enters the cell by endocytosis.<ref>{{cite journal | vauthors = Speeckaert MM, Speeckaert R, Delanghe JR | title = Biological and clinical aspects of soluble transferrin receptor | journal = Critical Reviews in Clinical Laboratory Sciences | volume = 47 | issue = 5-6 | pages = 213–228 | date = December 2010 | pmid = 21391831 | doi = 10.3109/10408363.2010.550461 }}</ref>
TfR1 is a transmembrane glycoprotein composed of two disulfide-linked monomers joined by two disulfide bonds. Each monomer binds one holo-[[transferrin]] molecule creating an iron-Tf-TfR complex which enters the cell by endocytosis.<ref>{{cite journal | vauthors = Speeckaert MM, Speeckaert R, Delanghe JR | title = Biological and clinical aspects of soluble transferrin receptor | journal = Critical Reviews in Clinical Laboratory Sciences | volume = 47 | issue = 5-6 | pages = 213–228 | date = December 2010 | pmid = 21391831 | doi = 10.3109/10408363.2010.550461 }}</ref>
Transferrin receptor protein 1 (TfR1), also known as Cluster of Differentiation 71 (CD71), is a protein that in humans is encoded by the TFRCgene.[1][2] TfR1 is required for iron import from transferrin into cells by endocytosis.[3][4]
TfR1 is a transmembrane glycoprotein composed of two disulfide-linked monomers joined by two disulfide bonds. Each monomer binds one holo-transferrin molecule creating an iron-Tf-TfR complex which enters the cell by endocytosis.[5]
Clinical significance
TfR1 as a potential new target in cases of human leukemia & lymphoma. InatherYs, in Évry, France, developed a candidate drug, INA01 antibody (anti-CD71) that showed efficacy in pre-clinical studies in the therapy of two incurable orphan oncohematological diseases: the adult T cell leukemia (ATLL) caused by HTLV-1 and the Mantle cell lymphoma (MCL).[citation needed]
↑Moos T (November 2002). "Brain iron homeostasis". Danish Medical Bulletin. 49 (4): 279–301. PMID12553165.
↑Speeckaert MM, Speeckaert R, Delanghe JR (December 2010). "Biological and clinical aspects of soluble transferrin receptor". Critical Reviews in Clinical Laboratory Sciences. 47 (5–6): 213–228. doi:10.3109/10408363.2010.550461. PMID21391831.
↑Green F, O'Hare T, Blackwell A, Enns CA (May 2002). "Association of human transferrin receptor with GABARAP". FEBS Lett. 518 (1–3): 101–6. doi:10.1016/S0014-5793(02)02655-8. PMID11997026.
↑West AP, Bennett MJ, Sellers VM, Andrews NC, Enns CA, Bjorkman PJ (December 2000). "Comparison of the interactions of transferrin receptor and transferrin receptor 2 with transferrin and the hereditary hemochromatosis protein HFE". J. Biol. Chem. 275 (49): 38135–8. doi:10.1074/jbc.C000664200. PMID11027676.
2nsu: Crystal structure of the ectodomain of human transferrin receptor fitted into a cryo-EM reconstruction of canine parvovirus and feline transferrin receptor complex